Muhammad Salim, MD
Pulmonary Disease · Chandler, AZNPI 1760467419
Payments from drug & device makers
Across 2,114 payments — averaging $2791.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$2.9M
- AstraZeneca$1.3M
- Sumitomo Pharma America, Inc.$334K
- Sanofi US Services Inc.$305K
- Bausch Health US, LLC$290K
- Cleerly, Inc.$164K
- plus $588K from 22 others
What the payments were for
- Travel & lodging$9369%
- Food & beverage$6626%
- Education$9,06385%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 1,483 | $2,938,180 |
| AstraZeneca | 19 | $1,281,641 |
| Sumitomo Pharma America, Inc. | 66 | $334,367 |
| Sanofi US Services Inc. | 55 | $305,378 |
| Bausch Health US, LLC | 213 | $290,247 |
| Cleerly, Inc. | 35 | $164,241 |
| Sanofi | 30 | $149,674 |
| Chiesi USA, Inc. | 47 | $132,950 |
| Alnylam Pharmaceuticals Inc. | 88 | $124,262 |
| Roche Molecular Systems, Inc. | 11 | $59,482 |
| Teva Pharmaceuticals USA, Inc. | 5 | $27,710 |
| Pfizer | 22 | $26,371 |
| Acadia Pharmaceuticals Inc | 6 | $24,000 |
| Astrazeneca UK Limited | 1 | $18,625 |
| CSL Behring | 2 | $14,000 |
| Intuitive Surgical | 12 | $9,957 |
| E.r. Squibb & Sons, L.L.C. | 1 | $499 |
| GSK | 5 | $98 |
| Mylan Specialty L.p. | 1 | $56 |
| Viatris Specialty LLC | 2 | $52 |
| Verona Pharma, Inc. | 2 | $48 |
| Genentech USA, Inc. | 1 | $40 |
| Gilead | 2 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Harmony Biosciences LLC | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Philips North America LLC | 1 | $19 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,859
- ION$3,000
How this compares
$5,902,002 in reported general payments places this provider in the 95th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Spiriva RespimatTiotropium Bromide | 95 | $59,895 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 80 | $57,852 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $49,744 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 283 | $41,366 |
| Breo ElliptaFluticasone/Vilanterol | 61 | $27,718 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 47 | $27,109 |
| SymbicortBudesonide/Formoterol Fumarate | 87 | $23,665 |
| Incruse ElliptaUmeclidinium Bromide | 35 | $17,277 |
| Atrovent HfaIpratropium Bromide | 29 | $14,385 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 455 | $13,384 |
| EliquisApixaban | 18 | $11,817 |
| Wixela InhubFluticasone Propion/Salmeterol | 138 | $11,811 |
| Fluticasone Propionate HfaFluticasone Propionate | 30 | $10,053 |
| Fluconazole | 279 | $9,879 |
| Arnuity ElliptaFluticasone Furoate | 20 | $8,202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $98 | $130,050228 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,281,641 | $81,517167 claims |
| PfizerEliquis | $26,371 | $11,81718 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $27,710 | $5,17314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Chandler
- Vikas SayalBullhead City$3.7M
- David BaratzPhoenix$2.2M
- James RossPhoenix$2M
- Rajat WaliaPhoenix$1.9M
- Robert OrrPeoria$1.6M
- Sachin ChaudharyTucson$1.2M
- Mark GotfriedPhoenix$1.1M
- George ParidesMesa$913K
- Richard SueGilbert$624K
- Abhinav MittalTucson$570K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.